In this issue, CEO Karin Bryder informs that ongoing procurement processes and negotiations with Swedish healthcare regions continued during the spring, with Kronoberg and Blekinge becoming the sixth and seventh region to be able to offer Efemia to its patients on October 1. She also comments on early signs indicating that the European healthcare systems are initiating a normalisation phase, and informs that the company’s preparatory work before applying for market approval of Efemia in the United States has continued as planned.

To read the newsletter, and subscribe for upcoming issues, follow this link:

https://bit.ly/invjun20en

The newsletter is published in Swedish and English, with a flexible publishing frequency based on Invent Medic’s news flow. It is produced together with the company’s IR communication partner Honeybadger, www.honeybadger.se. Invent Medic encourages feedback and requests on topics for upcoming issues of the newsletter.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com 

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.